文献速递神经免疫

NMDAR抗体脑炎免疫治疗使用与安全性的Meta分析

Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis.
PubMed 文献 · JAMA Neurol · 2021-01-01

该系统评价纳入652篇文章中1550例NMDAR抗体脑炎患者,分析免疫治疗使用与安全性、功能结局和复发预测因素。12个月良好功能结局与青少年年龄及一线治疗(血浆置换、激素联合IVIG或三联)相关;利妥昔单抗使用增加与复发率下降并行。影响功能结局与复发的因素不同,需独立考虑。

要点

  • 青少年年龄及一线血浆置换、激素联合IVIG或三联治疗与12个月良好功能结局相关。
  • 发病年龄<2岁或≥65岁、ICU入住、极度δ刷、30天内未免疫治疗及维持IVIG≥6个月与不良结局相关。
  • 利妥昔单抗或维持IVIG≥6个月与非复发病程相关,青少年年龄与复发相关。

核心结论

  • 影响NMDARE功能结局与复发的因素不同,制定循证管理指南时需独立考虑。

研究设计与样本

  • 系统检索PubMed自建库至2019年1月1日,纳入报告个体免疫治疗数据的NMDARE患者文章,共652篇、1550例。

主要发现

  • 12个月良好功能结局(mRS 0-2)与青少年年龄及一线血浆置换、激素联合IVIG或三联治疗显著相关。
  • 不良功能结局(mRS>2)与发病年龄<2岁或≥65岁、ICU入住、脑电图极度δ刷、30天内未免疫治疗及维持IVIG≥6个月显著相关。
  • 非复发疾病与利妥昔单抗使用或维持IVIG≥6个月显著相关,青少年年龄与复发显著相关。
  • 利妥昔单抗使用从13.5%(52/384,2007-2013)增至28.3%(311/1100,2013-2019)(P<.001),同期复发率从2008年及以前22%(12/55)降至2017年及以后10.9%(35/322)(P=.006)。
  • 改良NEOS评分(含5项中4项)与1年不良功能状态概率相关:0-1分20.1%(40/199),3-4分43.8%(77/176)(P=.05)。

关键数值与推荐

  • 良好功能结局定义为12个月mRS 0-2,不良为mRS>2;单相病程定义为24个月及以上无复发。
  • 一线治疗中血浆置换、激素联合IVIG或激素联合IVIG联合血浆置换与良好结局显著相关。
  • 利妥昔单抗或维持IVIG≥6个月与非复发疾病显著相关。

临床怎么用

  • 对NMDARE患者可考虑一线血浆置换、激素联合IVIG或三联治疗以改善12个月功能结局。
  • 对复发风险较高者(如青少年)可考虑利妥昔单抗或维持IVIG≥6个月,但需权衡安全性。
  • 改良NEOS评分可用于辅助预测1年功能状态,评分3-4分者不良结局概率较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Overall, immunotherapy has been shown to improve outcomes and reduce relapses in individuals with N-methyl-d-aspartate receptor (NMDAR) antibody encephalitis (NMDARE); however, the superiority of specific treatments and combinations remains unclear. OBJECTIVE: To map the use and safety of immunotherapies in individuals with NMDARE, identify early predictors of poor functional outcome and relapse, evaluate changes in immunotherapy use and disease outcome over the 14 years since first reports of NMDARE, and assess the Anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score. DATA SOURCES: Systematic search in PubMed from inception to January 1, 2019. STUDY SELECTION: Published articles including patients with NMDARE with positive NMDAR antibodies and available individual immunotherapy data. DATA EXTRACTION AND SYNTHESIS: Individual patient data on immunotherapies, clinical characteristics at presentation, disease course, and final functional outcome (modified Rankin Scale [mRS] score) were entered into multivariable logistic regression models. MAIN OUTCOMES AND MEASURES: The planned study outcomes were functional outcome at 12 months from disease onset (good, mRS score of 0 to 2; poor, mRS score greater than 2) and monophasic course (absence of relapse at 24 months or later from onset). RESULTS: Data from 1550 patients from 652 articles were evaluated. Of these, 1105 of 1508 (73.3%) were female and 707 of 1526 (46.3%) were 18 years or younger at disease onset. Factors at first event that were significantly associated with good functional outcome included adolescent age and first-line treatment with therapeutic apheresis, corticosteroids plus intravenous immunoglobulin (IVIG), or corticosteroids plus IVIG plus therapeutic apheresis. Factors significantly associated with poor functional outcome were age younger than 2 years or age of 65 years or older at onset, intensive care unit admission, extreme delta brush pattern on electroencephalography, lack of immunotherapy within the first 30 days of onset, and maintenance IVIG use for 6 months or more. Factors significantly associated with nonrelapsing disease were rituximab use or maintenance IVIG use for 6 months or more. Adolescent age at onset was significantly associated with relapsing disease. Rituximab use increased from 13.5% (52 of 384; 2007 to 2013) to 28.3% (311 of 1100; 2013 to 2019) (P < .001), concurrent with a falling relapse rate over the same period (22% [12 of 55] in 2008 and earlier; 10.9% [35 of 322] in 2017 and later; P = .006). Modified NEOS score (including 4 of 5 original NEOS items) was associated with probability of poor functional status at 1 year (20.1% [40 of 199] for a score of 0 to 1 points; 43.8% [77 of 176] for a score of 3 to 4 points; P = .05). CONCLUSIONS AND RELEVANCE: Factors influencing functional outcomes and relapse are different and need to be considered independently in development of evidence-based optimal management guidelines of patients with NMDARE.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Nosadini M, Eyre M, Molteni E, et al. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021. PMID: 34542573. doi:10.1001/jamaneurol.2021.3188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。